124 related articles for article (PubMed ID: 7504824)
1. The effect of the MAO-A selective inhibitor brofaromine on the plasma and urine concentrations of some biogenic amines and their acidic metabolites in bulimia nervosa.
Davis BA; Kennedy SH; Durden DA; D'Souza J; Goldbloom DS; Boulton AA
Prog Neuropsychopharmacol Biol Psychiatry; 1993 Sep; 17(5):747-63. PubMed ID: 7504824
[TBL] [Abstract][Full Text] [Related]
2. Effects of chronic brofaromine administration on biogenic amines including sulphatoxymelatonin and acid metabolites in patients with bulimia nervosa.
Kennedy SH; Davis BA; Brown GM; Ford CG; d'Souza J
Neurochem Res; 1993 Dec; 18(12):1281-5. PubMed ID: 7505890
[TBL] [Abstract][Full Text] [Related]
3. Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers.
Bieck PR; Firkusny L; Schick C; Antonin KH; Nilsson E; Schulz R; Schwenk M; Wollmann H
Clin Pharmacol Ther; 1989 Mar; 45(3):260-9. PubMed ID: 2920501
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term storage on the concentrations of the unconjugated acidic metabolites of the trace amines, indoleamines and catecholamines.
Davis BA
J Chromatogr; 1988 Dec; 433():23-30. PubMed ID: 2466860
[TBL] [Abstract][Full Text] [Related]
5. Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of brofaromine.
Kennedy SH; Goldbloom DS; Ralevski E; Davis C; D'Souza JD; Lofchy J
J Clin Psychopharmacol; 1993 Dec; 13(6):415-22. PubMed ID: 8120155
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.
Koulu M; Scheinin M; Kaarttinen A; Kallio J; Pyykkö K; Vuorinen J; Zimmer RH
Br J Clin Pharmacol; 1989 Feb; 27(2):243-55. PubMed ID: 2469451
[TBL] [Abstract][Full Text] [Related]
7. Reversible, amine--selective effects of acute and chronic brofaromine treatment in the rat.
Dyck LE; Boulton AA
Life Sci; 1992; 51(1):59-66. PubMed ID: 1614274
[TBL] [Abstract][Full Text] [Related]
8. Excretion of biogenic amine metabolites in anorexia nervosa.
Riederer P; Toifl K; Kruzik P
Clin Chim Acta; 1982 Aug; 123(1-2):27-32. PubMed ID: 6180848
[TBL] [Abstract][Full Text] [Related]
9. Urinary acid metabolites of biogenic amines in schizophrenic patients.
Domino EF
Schizophr Bull; 1980; 6(2):238-44. PubMed ID: 6154967
[TBL] [Abstract][Full Text] [Related]
10. Comparison of neurochemical effects of the monoamine oxidase inhibitors phenelzine, moclobemide and brofaromine in the rat after short- and long-term administration.
Urichuk LJ; Allison K; Holt A; Greenshaw AJ; Baker GB
J Affect Disord; 2000 May; 58(2):135-44. PubMed ID: 10781703
[TBL] [Abstract][Full Text] [Related]
11. Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: relationship to clinical improvement.
Celada P; Pérez J; Alvarez E; Artigas F
J Clin Psychopharmacol; 1992 Oct; 12(5):309-15. PubMed ID: 1282522
[TBL] [Abstract][Full Text] [Related]
12. Urinary levels of biogenic amine metabolites in mentally retarded children.
Nalini K; Aroor AR; Rao A
J Ment Defic Res; 1988 Oct; 32 ( Pt 5)():419-24. PubMed ID: 2462053
[TBL] [Abstract][Full Text] [Related]
13. Serotonin uptake inhibition by the monoamine oxidase inhibitor brofaromine.
Waldmeier PC; Graf T; Germer M; Feldtrauer JJ; Howald H
Biol Psychiatry; 1993 Mar; 33(5):373-9. PubMed ID: 8471696
[TBL] [Abstract][Full Text] [Related]
14. Correlations of plasma and urinary phenylacetic acid and phenylethylamine concentrations with eating behavior and mood rating scores in brofaromine-treated women with bulimia nervosa.
Davis BA; Kennedy SH; D'Souza J; Durden DA; Goldbloom DS; Boulton AA
J Psychiatry Neurosci; 1994 Jul; 19(4):282-8. PubMed ID: 7918350
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hyperactive children with monoamine oxidase inhibitors. II. Plasma and urinary monoamine findings after treatment.
Zametkin A; Rapoport JL; Murphy DL; Linnoila M; Karoum F; Potter WZ; Ismond D
Arch Gen Psychiatry; 1985 Oct; 42(10):969-73. PubMed ID: 2412521
[TBL] [Abstract][Full Text] [Related]
16. Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A.
Garcia-Borreguero D; Lauer CJ; Ozdaglar A; Wiedemann K; Holsboer F; Krieg JC
Pharmacopsychiatry; 1992 Nov; 25(6):261-4. PubMed ID: 1494591
[TBL] [Abstract][Full Text] [Related]
17. Regional action of brofaromine on rat brain MAO-A and MAO-B.
Gerardy J; Dresse A
Prog Neuropsychopharmacol Biol Psychiatry; 1998 Oct; 22(7):1141-55. PubMed ID: 9829294
[TBL] [Abstract][Full Text] [Related]
18. D-lysergic acid diethylamide (LSD)--effect on biogenic amines excretion in man.
Messiha FS; Grof S
Biochem Pharmacol; 1973 Sep; 22(18):2352-4. PubMed ID: 4733686
[No Abstract] [Full Text] [Related]
19. Effects of monoamine oxidase A inhibition on plasma biogenic amine metabolites in depressed patients.
Markianos M; Alevizos B; Hatzimanolis J; Stefanis C
Psychiatry Res; 1994 Jun; 52(3):259-64. PubMed ID: 7527564
[TBL] [Abstract][Full Text] [Related]
20. Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrations.
Fritze J; Becker T; Ziegler V; Laux G; Riederer P
Pharmacopsychiatry; 1990 May; 23(3):131-4. PubMed ID: 2374771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
